Epigallocatechin gallate
Small molecule targets CD4 via inhibition
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05680662 | Jan → Dec 2023 | female breast carcinoma, triple-negative breast carcinoma | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05195918 | Aug 2023 → Mar 2026 | idiopathic pulmonary fibrosis | Hal Chapman | Completed | No outcome recorded |
| Phase 1 | NCT05116098 | Nov 2021 → Jun 2022 | tuberculosis | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 1 | NCT04177693 | Nov 2020 → Jan 2022 | leiomyoma | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03278925 | Aug 2018 → Jun 2023 overdue | cirrhosis of liver | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01433289 | Dec 2010 → Aug 2014 | HIV infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00476138 | Nov 2006 → Jul 2008 | ocular hypertension, open-angle glaucoma | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07647198 | Aug 2026 → Aug 2029 expected | leiomyoma | Sheikh Shakhbout Medical City | Recruiting | No outcome recorded |
| Phase 2 | NCT07572396 | Apr → Dec 2026 expected | cervix disorder, dysplasia of cervix, human papilloma virus infection, squamous cell intraepithelial neoplasia | Amplexd Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06068543 | Oct 2024 → Jan 2030 | — | University of Rochester | Suspended | No outcome recorded |
| Phase 2 | NCT06015022 | Sep 2024 → Aug 2028 expected | cirrhosis of liver | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06098456 | Nov 2023 → May 2024 | papilloma | Centro di Ricerca Clinica Salentino | Completed | No outcome recorded |
| Phase 2 | NCT02577393 | Apr 2015 → Jun 2022 | esophagitis, lung neoplasm | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01511263 | Jan 2012 → Jul 2016 | AL amyloidosis | Fondazione IRCCS Policlinico San Matteo di Pavia | Terminated | No outcome recorded |
| Phase 2 | NCT00005097 | Aug 1999 → Aug 2002 | skin carcinoma | Frank Meyskens | Terminated | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT04446065 | Sep 2020 → Sep 2021 | COVID-19 | MELISA Institute Genomics & Proteomics Research SpA | Unknown | No outcome recorded |
| Phase 2/3 | NCT02483156 | Jul → Aug 2015 | chronic hepatitis C virus infection | Egyptian Liver Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02147041 | May 2012 → Aug 2014 | diabetes mellitus, hyperlipidemia | Taipei City Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00951834 | Oct 2009 → Feb 2015 | Alzheimer disease | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2/3 | NCT00799890 | May 2009 → Mar 2016 | multiple sclerosis | Friedemann Paul | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT02832271 Comparator | Dec 2016 → Dec 2022 | endometriosis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT01923597 Comparator | Nov 2013 → Mar 2015 | diabetic kidney disease, hypertensive disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 2 | NCT00134381 Comparator | May 2003 → Nov 2012 | — | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01183767 Comparator | Dec 2010 → Sep 2018 | Duchenne muscular dystrophy | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02008721 Comparator | Jan 2014 → Sep 2016 | multiple system atrophy | Dr. Johannes Levin | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epigallocatechin Gallate | “Several lines of evidence including epidemiological, in vitro, and in vivo data, suggest that Epigallocatechin gallate (EGCG) might be able to delay disease progression of MSA...” NCT02008721 ↗20“In this study, the effect of (-)-epigallocatechin-gallate (EGCG) of tea leaves (Camellia sinensis) combined with the first-line OAT will be observed, in order to find out...” NCT05116098 ↗ “The patients will receive four capsules Polyphenol E - epigallocatechin gallate (Polyphenon Pharma, NY) per day, corresponding to 800 mg of epigallocatechin gallate (EGCG), or...” NCT01923597 ↗ “Determine the efficacy of the green tea extract epigallocatechin gallate (Polyphenon E topical ointment) in causing complete clinical and histopathologic regression in patients...” NCT00005097 ↗ “caffeine or (-)-epigallocatechin gallate; EGCG] have a protective effect on skin exposed to ultraviolet light (UV).” NCT00134381 ↗ “We developed the novel formulation Catvira, composed of epigallocatechingallate (EGCG) + sofosbuvir + ribavirin.” PMID 33633233 ↗ Feb 2021 “defined green tea catechin extract (Polyphenon E/epigallocatechin gallate [EGCG]) treatment” NCT03278925 ↗ “Epigallocatechin gallate + Quinine Sulfate - Dysplasix™ Semisolid Intravaginal suppository” NCT07572396 ↗ “Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg” NCT06098456 ↗ “We recently identified epigallocatechin gallate (EGCG), a trihydroxyphenolic compound” PMID 33472968 ↗ Jan 2021 “Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.” PMID 33622766 ↗ Feb 2021 “Polyphenon E capsules containing 200 mg of epigallocatechin-gallate.” NCT01433289 ↗ “Epigallocatechin gallate (EGCG) and vitamin D3 supplementation” NCT07647198 ↗ “Dietary Supplement: Epigallocatechin gallate (EGCG)” NCT04177693 ↗ “SST plus Epigallocatechin gallate (EGCG).” NCT01511263 ↗ “EGCG(Epigallocatechin Gallate)” NCT02147041 ↗ |
| Known as | EGCG | “Several lines of evidence including epidemiological, in vitro, and in vivo data, suggest that Epigallocatechin gallate (EGCG) might be able to delay disease progression of MSA...” NCT02008721 ↗15“In this study, the effect of (-)-epigallocatechin-gallate (EGCG) of tea leaves (Camellia sinensis) combined with the first-line OAT will be observed, in order to find out...” NCT05116098 ↗ “Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure” NCT00134381 ↗ “We developed the novel formulation Catvira, composed of epigallocatechingallate (EGCG) + sofosbuvir + ribavirin.” PMID 33633233 ↗ Feb 2021 “BACKGROUND: Epigallocatechin-gallate (EGCG) is a powerful antioxidant with suggested neuroprotective action.” PMID 19290537 ↗ Mar 2009 “defined green tea catechin extract (Polyphenon E/epigallocatechin gallate [EGCG]) treatment” NCT03278925 ↗ “We recently identified epigallocatechin gallate (EGCG), a trihydroxyphenolic compound” PMID 33472968 ↗ Jan 2021 “Epigallocatechin-Gallate (EGCG, the major polyphenol in green tea)” NCT01183767 ↗ “Dietary Supplement: Epigallocatechin gallate (EGCG)” NCT04177693 ↗ “Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:” NCT00951834 ↗ “daily oral EGCG (300 mg) and vitamin D3 (2000 IU)” NCT07647198 ↗ “SST plus Epigallocatechin gallate (EGCG).” NCT01511263 ↗ “Epigallocatechin gallate (EGCG)” NCT06015022 ↗ |
| Known as | epigallocatechin-3-gallate | “The down-regulation of TACO gene expression by epigallocatechin-3-gallate was accompanied by inhibition of mycobacterium survival within macrophages as assessed through flow...” NCT05116098 ↗ |
| Known as | Epigallocatechin-3-Gallate (EGCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06068543 ↗ |
| Known as | Polyphenon E | “Determine the efficacy of the green tea extract epigallocatechin gallate (Polyphenon E topical ointment) in causing complete clinical and histopathologic regression in patients...” NCT00005097 ↗1“defined green tea catechin extract (Polyphenon E/epigallocatechin gallate [EGCG]) treatment” NCT03278925 ↗ |
| Known as | Previfenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04446065 ↗ |
| Known as | SUNPHENON EGCg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02832271 ↗ |
| Action | Inhibit | “Sunphenon EGCg has an antiinflammatoric effect due to its impact on the T-cell-proliferation and the inhibition of the activity of NF-Kb.” NCT00799890 ↗ |
| Modality | Small molecule | “EGCG, the major polyphenol in green tea” NCT01183767 ↗ |
| Route | Topical | “topical epigallocatechin gallate” NCT00005097 ↗ |
| Target | CD4 | “Studies have demonstrated evidence of high affinity binding of EGCG to the CD4 molecule” NCT01433289 ↗ |